Iambic Therapeutics Recognized in Endpoints 11 Most Promising Biotech Startups
Iambic Therapeutics, a clinical-stage biotech company harnessing its AI-driven discovery platform, has been named to the 2024 Endpoints News list of “Biotech’s Most Promising Startups.” This annual award highlights innovative life science companies working to develop breakthrough therapies. “By integrating…
Bristol Myers Squibb Unveils Sotyktu Efficacy Data for Scalp Psoriasis in Two Trials
Bristol Myers Squibb (NYSE:BMY) has announced promising results from the Phase 3b/4 PSORIATYK SCALP trial, which assessed the efficacy of Sotyktu (deucravacitinib) in treating patients with moderate-to-severe scalp psoriasis, including those with less extensive psoriasis. The trial met its primary…
Naveris Unveils NavDx® Test Data for HPV-Linked Oropharyngeal Cancer at 2024 AAO-HNS Meeting
Naveris, Inc., a leader in precision oncology diagnostics for viral-induced cancers, announced new data presentation at the 2024 Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), held from September 28 to October 1, 2024, in Miami…
Next Health to Open Proactive Healthcare Centers in Tampa and St. Petersburg
Next Health, a leader in proactive healthcare, is set to open two health optimization and longevity centers in Tampa and St. Petersburg under an area development agreement. This move comes after the brand’s recent expansion in Florida, where it added…
New Data: DecisionDx®-SCC Outperforms BWH Staging for High-Risk Skin Cancer Treatment
Castle Biosciences, Inc. (Nasdaq: CSTL), a company focused on improving health through innovative diagnostic tests, announced new data showing that its DecisionDx-SCC test offers clinically significant risk stratification for high-risk SCC patients, particularly those with suppressed immune systems. This enhanced…
Covalon Technologies to Attend 2024 Vascular Access Scientific Meeting
Covalon Technologies Ltd. (TSXV: COV; OTCQX: CVALF) is pleased to announce its participation in the 2024 Association for Vascular Access (AVA) Annual Scientific Meeting, scheduled from September 28 to 30 in Colorado. Founded in 1985, AVA is a multidisciplinary organization…
Caresyntax Wins 2024 German AI Prize for Surgical Intelligence Innovation
Caresyntax, a leading company in surgical intelligence and automation, has won the prestigious 2024 German AI Prize. The awards were presented by Germany’s Federal Minister for Digitalization, Volker Wissing, at a ceremony in Berlin on September 26, 2024. The German…
GE HealthCare’s Flyrcado PET Radiotracer Gains FDA Approval for Better Coronary Artery Disease Diagnosis
GE HealthCare announced that the FDA has approved Flyrcado™ (flurpiridaz F 18) injection, a groundbreaking PET myocardial perfusion imaging (MPI) agent, for detecting coronary artery disease (CAD). Flyrcado offers higher diagnostic accuracy than the widely used SPECT MPI and is…
FDA Approves Bristol Myers Squibb’s COBENFY™ for Schizophrenia Treatment
Bristol Myers Squibb (NYSE: BMY) has announced FDA approval of COBENFY™ (xanomeline and trospium chloride), an oral medication for treating schizophrenia in adults. COBENFY is the first new class of schizophrenia treatment in decades, offering a novel approach by selectively…
Establishment Labs Gains FDA Approval for Motiva Implants
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on enhancing women’s health, has received U.S. FDA approval for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in both primary and revision breast…
New Data Highlights Reliability and Benefits of Perspectum’s MRI for Metabolic Liver Disease
Perspectum recently announced two published research studies that offer hope to those with metabolic dysfunction-associated steatohepatitis (MASH). The studies validate the effectiveness of quantitative MRI imaging as a potential alternative to liver biopsy in certain clinical trials and patient care…
Phare Bio Secures Up to $27M from ARPA-H to Boost AI-Driven Antibiotic Discovery
Phare Bio, in collaboration with the Collins Lab at MIT and Harvard’s Wyss Institute, announced they have secured up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), a division of the U.S. Department of…